Genomic loss of heterozygosity and survival in the REAL3 trial

BACKGROUND: Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers will have high-LOH which would be prognostic in patients treated with platin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Smyth, Elizabeth C., Cafferkey, Catherine, Loehr, Andrea, Waddell, Tom, Begum, Ruwaida, Peckitt, Clare, Harding, Thomas C., Nguyen, Minh, Okines, Alicia F., Raponi, Mitch, Rao, Sheela, Watkins, David, Starling, Naureen, Middleton, Gary W., Wadsley, Jonathan, Mansoor, Wasat, Crosby, Tom, Wotherspoon, Andrew, Chau, Ian, Cunningham, David
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6291175/
https://ncbi.nlm.nih.gov/pubmed/30613349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26336
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados